Background: Polycystic Ovarian Syndrome (PCOS) is a common, complex,
1) Introduction
'Polycystic ovary syndrome is a frustrating experience for women, often complex for managing clinicians and a scientific challenge for researchers' (Teede et al. 2010, p1) . PCOS was first identified by Irving Stein and Michael Leventhal in 1935, whilst conducting a case study of seven women exhibiting the collection of symptoms of hirsutism, obesity, amenorrhea, and enlarged ovaries. Today, PCOS is recognised as a complex, heterogeneous, endocrine and metabolic condition with multiple aetiologies and clinical presentations with long term health implications. Although the exact aetiology is unknown, insulin resistance and compensatory hyperinsulinemia are now understood to play key roles (Dunaif, 1997) .
Definition and diagnosis:
PCOS is one of the most common endocrine disorders in women of reproductive age. However, its definition and diagnosis remains controversial. The prevalence of PCOS is dependent on which definition is used; the National Institute of Health (NIH; 1990) at 6% or the Rotterdam (2003) at 15% (Fauser et al. 2012 ).
At present, the Rotterdam definition is the most widely accepted stating that women with PCOS will have a combination of two of the following:
• Chronic anovulation
• Clinical and/or biochemical signs of hyperandrogenism
• Polycystic ovaries on ultra sound with the exclusion of other androgen excess or related disorders. These may include hyperprolactinema; abnormal thyroid function; non classical 2-hydroxylase deficiency and androgen secreting tumours. 1 1 Chronic anovulation can be defined as absence of ovulation. Clinical signs of hyperandrogenism may include include hirsutism, alopecia, acanthosis nigricans and acne. Biochemical signs of hyperandrogenism include raised levels of androgens. Polycystic ovaries are defined as presence of 12 or more follicles in each ovary measuring 2±9 mm in diameter, and/or increased ovarian volume (>10 ml) A c c e p t e d M a n u s c r i p t
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The NIH definition is the strictest, whilst the Rotterdam incorporates a broader spectrum of symptoms, notably polycystic morphology and the inclusion of women with hirsutism and regular menstruation. The Androgen and PCOS Society (Azziz et al. 2006 ) have proposed a further definition which concentrates on androgen excess.
Of note is the fact that the choice of finition used subsequently affects the validity of the outcomes of clinical trials and research analysis (Welt 2006 , Di Marcantonio 2008 .
Standard biochemical tests to assist in the diagnosis of PCOS measure total testosterone, free testosterone, dehydroepionadrosterone (DHEA), glucose tolerance, insulin sensitivity, cholesterol, thyroid hormones and prolactin. Sex hormone binding globulin (SHBG) is sometimes tested. Historically, luteinising hormone (LH) and follicle stimulating hormone (FSH) ratios were tested but are rarely used now due to their poor specificity (Dunaif 1997) .
Recently there have been calls to change the name of PCOS as it has been perceived as confusing to both women with the syndrome and healthcare providers (Dunaif and Fauser, 2013) . It has been proposed to re-name the syndrome to reflect the broader clinical significance and enhance recognition of its multi-faceted features (Teede et al. 2014 Aetiology: The aetiology of PCOS remains elusive as currently there are no specific genetic or metabolic markers. However, there is evidence of a genetic link in first degree female relatives (Kashar-Millar et al. 2001) and that physical and environmental factors, such as obesity, nutrition and pollutants may be influential (Kandaraki 2009 ).
Pathophysiology:
The pathophysiology is not well established. Different ideas on its development may well be interlinked:
• Metabolic derangements leading to insulin resistance and hyperandrogenism.
• A primary neuroendocrine defect leading to elevated LH, Gonadotrophin releasing hormone (GnRH) pulse frequency and amplitude.
• Inflammation and role of adipose tissue: adipokines, adiponectin and resistin, hormones that are secreted by adipose tissue have been indicated in the pathogenesis of PCOS (Carmina et al. 2005 ).
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A c c e p t e d M a n u s c r i p t 5 Insulin resistance resulting in hyperinsulinemia was first identified by Burghen (1980) as playing a key role in the pathogenesis of PCOS. Dunaif (1997) developed this finding to show that insulin resistance has a variety of circulatory, metabolic, hormonal and inflammatory consequences on the body. Hyperinsulinemia is understood to be the pathogenic mechanism involved in the development of hyperandrogenism. High levels of insulin stimulate the ovaries and adrenals to over produce androgens. This results in the absence of ovulation and consequent hyperandrogenism. Hyperinsulinemia decreases the hepatic production of the sex hormone binding globulin, which in turn further increases the amounts of circulating androgens. Insulin resistance is present in skeletal muscle and adipose tissue. With PCOS, there are defects in both insulin action and secretion and the molecular mechanisms differ from those found in obesity and NIDDM (Dunaif 1997) . The GnRH frequency in the hypothalamus is higher than normal. This results in increased levels of LH relative to FSH. This hormonal imbalance further results in increased levels of androgens.
Clinical manifestations: PCOS is often multifactorial in terms of signs and symptoms and these may vary in character and intensity during the different stages of a woman's lifetime.
• Anovulatory infertility: 50-70% of women with anovulatory infertility have PCOS (Pangariuan 2011). Approximately 90%-95% of anovulatory women presenting to infertility clinics have PCOS (Sirmans and Pate, 2014) . The economic burden of diagnosing and treating this is estimated to be up to £22 million annually in the UK (University of Nottingham PCOS Research Group, 2014 ).
• Amenorrhea, or oligomenorrhea: Up to 95% of affected women may have oligio or amenorrhea (Kumareplel et al. 2008 ).
• Hirsutism: Occurs in approximately 60% of cases; however this varies with race and degree of obesity (Azziz et al. 2006 ).
• Hyperinsulinemia: Reported in 50-80% of women with PCOS (Legro, 2004) .
Data further suggests that the severity of fasting hyperinsulinemia is associated with the severity of the clinical phenotype of hyperandrogenism, independent of obesity (Diamanti-Kandarakis et al.1999 ).
• Dyslipidemia: Women with PCOS are 1.5-2.0 more likely to have dyslipidemia than age matched controls (Azziz, 2007) . The most frequently Page 6 of 40 A c c e p t e d M a n u s c r i p t 6 observed pattern consists of high triglycerides, high low-density lipoprotein (LDL) and low high-density lipoprotein (LDL), a similar biochemical pattern to NIDDM and associated with insulin resistance (Brunzell and Ayydei, 2003) .
• Obesity: Estimated that 50% of women with PCOS suffer from obesity (Azziz et al. 2004) . It is an important factor in the development and complications of the syndrome; worsening insulin resistance and exacerbating reproductive and metabolic features (Balen 1995) . Central adiposity is a particular feature of PCOS, even in normal weight women (Garruti 2009 ).This can be evaluated using weight to hip ratio (WHR) calculations.
• Acne: Reported in 38% of women with PCOS (Borgia 2004).
• Acanthosis nigricans (AN): One study found a 23% prevalence (Sivayoganathan et al. 2011) . It is more common in South Asian women and strongly associated with insulin resistance.
• Male pattern alopecia: One study found a prevalence of 16% in women with PCOS (Sivayoganathan et al. 2011) • Obstructive sleep apnoea (OSA): The risk for OSA is 5-10 times higher than in obese women without PCOS and is linked to an increase in adverse cardiovascular events (Ehrmann et al. 2012 ).
• Anxiety and depression: More prevalent in women with PCOS. However it remains unclear whether this is due to the pathophysiology of the syndrome or as a consequence of the symptoms (Deeks 2012).
Phenotypes of PCOS:
An important new focus of research in the field of PCOS is the determination of the range of PCOS phenotypes. Phenotypes are a consequence of genotype combined with environmental factors such as diet, exercise, smoking, ethnicity, and age. Welt et al. (2006) found that women with PCOS characterised by regular menstruation and hyperandrogenism are the most severely affected in terms of insulin resistance and the consequential metabolic complications. Whereas Barber et al. (2007) found that those with normal androgen levels but polycystic ovaries and irregular menstruation had an almost normal metabolic profile in comparison to controls.
This highlights the importance of identifying a women's phenotype, screening appropriately and treating in response to the long term complications of the phenotype. This may help direct the focus away from debating PCOS definitions to A c c e p t e d M a n u s c r i p t 7 responding to the wide variations in which women with PCOS may present and any future health implications.
Long term health implications:
Women with PCOS have significant long term health implications. Sufferers have increased risk of developing; metabolic syndrome (Grundy et al. 2005) ; impaired glucose tolerance; gestational diabetes and noninsulin dependent diabetes mellitus (NIDDM) (Dunaif 1997 , Boomsma et al. 2006 , Teede et al. 2010 , Erhmann et al. 1999 . Morgan et al. (2012) (Hardiman et al. 2003) . There has been no confirmed correlation with breast, vaginal, vulval, cervical or ovarian cancers.
Dyslipidemia is associated with PCOS (Wild, 2012) and Randeva and al. (2012) additionally identified a correlation between PCOS and an increased prothrombotic state. However, the overall cardio-vascular disease (CVD) morbidity and mortality of PCOS patients remains unconfirmed, with conflicting evidence. Howlett's et al. study (2012) , over a 20 year period found an increased risk of myocardial infarction (0.2% to1.9%) and angina (0.8% to 2.5%) in age matched controls.
Whereas Schmidt et al. (2012) , in a 21 year follow up of PCOS patients, found no increase in stroke or myocardial infarction in comparison to controls. However, the sample size and controls are not directly comparable due to the large sample size in Howlett's, (PCOS, n=2, 353) and controls (n=432,506) and small sample size in Schmidt's (PCOS, n=32) and controls (n=95). Nevertheless, both sets of research confirm the increased dyslipidemia observed in women with PCOS. However the data on the frequency of primary CVD events in women with PCOS remains inconclusive. There is a paucity both of long-term data for well-characterized women A c c e p t e d M a n u s c r i p t 8 with PCOS, and for large-scale prospective clinical trials to determine the outcome morbidity and mortality of CVD in PCOS subjects.
As established, there are significant health risks that may impact morbidity and mortality. The health economic burden of PCOS in the USA has been estimated as ranging from $ 93 million to $ 1.77 billion annually (Azziz et al. 2005 ).
Unfortunately, comparative statistics are currently unavailable for the UK. Experts agree that more cohort and longitudinal studies are urgently needed to confirm the long term consequences of PCOS, evaluate risk and construct effective screening programs. Timely diagnosis, treatment and lifestyle modifications can be very effective in minimizing these complications (Bargiota et al. 2012 , Teede et al. 2010 ).
Current medical treatment strategies
'There is currently no ideal medical PCOS therapy that fully reverses underlying hormonal disturbances and treats all clinical features' (Teede et al. 2010, p6 ). • Progestins: such as Medroxyprogesterone acetate (MPA), these are synthetic variants of progesterone. They are used primarily for dysfunctional uterine bleeding and hirsutism. However they can cause side effects such as weight gain, fluid retention, liver dysfunction and depression (Romm, 2010) • Anti-androgens: such as cyproterone acetate, spironolactone or flutamide are used in women with PCOS primarily to treat hirsutism.
They are most often prescribed with the OCP due to the risk of fetus M a n u s c r i p t 9 feminisation in pregnancy and are therefore not appropriate for women seeking fertility outcomes.
• Insulin sensitizing drugs: Metformin has emerged as the most effective new treatment in respect of hyperinsulinemia and its metabolic consequences, with some suggesting a long awaited cure for women with PCOS. However, recent investigation by Tang et al. (2012) has identified that it is of no benefit in improving weight loss, insulin sensitivity, nor lipid profiles in women with PCOS. Additionally, some women may suffer debilitating gastrointestinal disturbance and rarer complications of renal impairment and lactic acidosis (Teede at al. 2007 ).
• Clomiphene: Legro (2007) found that this was more successful than metformin in regards to live birth rate in women seeking fertility outcomes. Whereas a recent meta-analysis found no difference in success rate between the two (Palomba 2009).
• Lifestyle changes: advocated as a first line evidence based approach for those women with PCOS who are overweight (Moran et al. 2009 ).
Some patients with PCOS can resume menstrual cycles and ovulation after having reduced only 5% of their body weight (Kiddy et al. 1992 ).
Emerging medical options;
• Statins: recent research has indicated statins may be a treatment for PCOS, reducing hyperandrogenism and improving lipid profile (Duleba 2012) . However this therapeutic intervention remains a controversial option due to their potential side effects.
Prescribed medications for PCOS often have significant side effects and contraindications. This proves especially problematic for women wishing fertility outcomes and those prescribed long-term medication. Additionally, some of the therapeutic interventions, although beneficial for some of the aberrations, might exacerbate others (Bargiota et al, 2012) .
Women with PCOS may present to gynaecologists, primary care physicians, endocrinologists, dermatologists, or other health care professionals, due to the wide variability of symptoms. Consequently, symptoms are often viewed and treated in M a n u s c r i p t 10 isolation, rather than as interlinked manifestations of this complex endocrine and metabolic medical syndrome.
Results from a questionnaire of 648 women with PCOS (Sills et al. 2001) , suggest that medical treatment frequently falls short of patients' expectations. 'The investigation detected a strong receptiveness among PCOS women regarding any safe and effective alternative to PCOS management' (Sills, 2001, p8) .
Herbal medicine and PCOS
Medical herbalists are health care providers trained in Western orthodox medical diagnosis that use unpurified plant extracts containing numerous phytochemicals to treat their patients. They use a poly-pharmacy approach, combining different herbs in each prescription (Pal and Shukalr, 2003) . Each prescription is different and adapted to the individual patient rather treating a determined condition. Lifestyle and nutritional recommendations are important aspects of a medical herbalist's treatment plan which takes an integrated and holistic approach. The traditional treatment strategies a medical herbalist may follow when treating a women with PCOS include: reducing insulin resistance; initiating ovulation and regulation of the menstrual cycle; decreasing androgens; improving hirsutism; supporting adrenal function; supporting liver function and reducing CVD risk.
Throughout history, herbal medicine has been used to treat symptoms related to PCOS. Today, successful results are frequently reported by both practitioners and patients. Nevertheless, there remains a significant lack of scientific research validating the use of herbal medicine in the treatment of PCOS. Producing high quality herbal research is challenging due to the lack of uniformity in herbal prescriptions and additionally, sourcing funding. Chinese herbal medicine (CHM) has benefitted from more robust scientific interest, in particular with PCOS related infertility (Zhang et al. 2010 , Kuek at al. 2011 ). Some of the herbs used in CHM, are incorporated into Western herbal medicine but often in very different formula so limited information may be extrapolated.
There exist a limited number of reviews on the treatment of PCOS with phytotherapy (Hywood, 2012; Trickey, 1999; Hywood and Bone, 2004; Nagarantha 2014) , however, there are no comprehensive reviews of published research on the subject nor surveys of practitioners' experiences treating the syndrome.
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Research Aim
The main aim of this study was to evaluate whether there is a role for phytotherapy in the management of PCOS. Current literature on PCOS and phytotherapy was reviewed and results compared with the experiences of medical herbalists who have treated women with the syndrome.
Robust empirical evidence combined with high quality research will provide a stronger evidence base for the herbal practitioner to successfully treat women with PCOS. Additionally, successful results from herbal treatment may serve to direct areas of future scientific research. 
2.2) Practitioner survey
Participants were qualified medical herbalists who were listed on the National Institute of Medical herbalists register of qualified members, 2012-13. An anonymous survey platform was utilized to distribute the questionnaire: Surveygizmo (www.surveygizmo.com). Participants were emailed inviting them to take part in the questionnaire, accessed through a hyperlink. The final version was distributed on 
Data analysis methods:
Descriptive statistics illustrate the majority of the data collected. However, a Spearman's rank correlation co-efficient was chosen as a form of inferential statistics.
3) Results

3.1) Literature review: Herbal medicine and PCOS
A total of 9 studies were selected ranging from animal models to randomized placebo controlled trials. The review identified papers in direct relation to PCOS and herbal medicine rather than researching herbs by action that may be appropriate in the treatment of PCOS. All studies identified by the search terms were included. Of note, no papers were identified specifically addressing the treatment of PCOS with Western herbal medicine.
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The two compounds have opposite effect on mineralcorticoid effector mechanism.
Useful research for using pharmacological drugs and herbs concurrently.
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3.3) Results of the herbal practitioner questionnaire
The response rate was 17%; 72 responded out of a total of 428 contacts, 9 unsubscribed from the questionnaire. A total of 72 practitioners completed the survey, 51 had treated women with PCOS giving a 71% treatment rate. The prevalence of symptoms for which patients sought treatment is illustrated by Fig. 1 below. 
Note: practitioners may have identified more than one symptom
Diet and lifestyle advice
A variety of dietary and lifestyle advice was given by practitioners. The most common theme that emerged was that 'diet is of fundamental importance in managing PCOS,' followed by taking regular exercise, and avoiding refined sugar.
Managing stress levels, increasing vegetable intake and following low glycaemic 
Treatment strategies
In terms of additional information and themes identified in the treatment of PCOS, hirsutism was cited as the most difficult to treat by eight of the respondents.
The next most frequent recommendation was to consider each patient as unique.
Subsequently, weight loss was identified as an important recommendation to reduce symptoms of PCOS. A total of twenty-seven herbs were identified from the questionnaire in response to a request for practitioners to state the three herbs they used the most in their treatment of PCOS ( Table 2) . Paeonia lactiflora, Glycyrrhiza glabra and Vitex agnus were identified as the most frequently prescribed herbs with the use of tinctures and fluid extracts being practitioners main choice of formulation..
Herbs prescribed by practitioners in the treatment of PCOS
Successful treatment and timing
Fifty practitioners responded to the question on the success of their herbal treatment. 2% (n=1) reported a small improvement, 36% (n=18) reported a reasonable improvement, 38% (n=19) were quite successful and 24% (n=12) 
Concurrent pharmaceutical medication
Fifty practitioners responded to the question of whether patients were taking concurrent pharmaceutical medication during their herbal treatment. 45% (n=23) practitioners responded that their patients were taking concurrent pharmaceutical medication. The oral contraceptive and Metformin were most frequently cited, followed consecutively by Spironolactone, Finesteride and glucocorticoids.
Insulin resistance
Fifty-five practitioners responded to the question 'Is insulin resistance a key factor in PCOS'. 82% (n=45) of practitioners agreed whilst 16% (n=9) felt neutral about this statement and 2% (n=1) disagreed. 
4) Discussion
The current study confirms that women with PCOS are seeking treatment for their symptoms from herbal practitioners. Of the seventy two respondents in the practitioner questionnaire, 71% (n=51) had treated women with this condition.
National figures are unavailable for the treatment ratios of herbal practitioners; nevertheless, this preliminary study does suggest it is a condition many have treated.
It would be valuable to quantify numbers of women with PCOS presenting to herbal practitioners and this could be achieved by conducting a national treatment survey.
The questionnaire highlighted that the symptom patients presented with most frequently was menstrual irregularity (figure 1). Strowitzki (2010) showed that, in women with PCOS, menstrual irregularity is often a symptom of women with the most endocrine and metabolic abnormalities, and possible long term health risks.
Consequently, it is important that herbal practitioners recognise the potential indications of this symptom in PCOS, and refer appropriately for further investigation to rule out associated endocrine and metabolic pathologies. A c c e p t e d M a n u s c r i p t 21 tentative evidence does suggest that the longer a patient has herbal treatment, the more successful it will be. Practitioners may want to incorporate this finding into their prognosis for women with PCOS ( Figure 2) A confounding variable was that many patients treated by practitioners may have been concurrently taking pharmaceutical medications. Therefore, these results may have been in part due to the action of these drugs rather than herbal treatment.
Additionally, it is important to clarify that the practitioner's view of start of the successful treatment may vary from that of the patient. Future investigation into herbal treatment without concurrent medication, patient's experiences of herbal treatment and biochemical analysis is necessary to substantiate these results.
In the questionnaire, the most commonly used herbs by practitioners were Paeonia lactiflora, Glycyrhhiza glabra and Vitex agnus castus (Table 2) tincture; (7mls). This is based on Japanese research indicating this herbal combination decreases testosterone levels in women with PCOS (Takahashi et al.
1994).
Glycyrrhiza glabra was the second most popular choice. It has been reviewed in terms of PCOS in the literature review ( Table 1) . Other studies in non-PCOS women have shown it has an anti-androgenic action (Armanini at al. 2004) and suggested that this effect is due to the ability of the constituents of Glycyrrhiza glabra to block 17-hydroxysteroid dehyrogenase and 17-20 lyase. Pharmacological investigation on rats has shown that glycyrrhetinic acid, a constituent of Glycyrrhiza glabra significantly decreases testosterone production from the rats' ovaries (Takeuchi et al, 1991) . Further research suggests that glycyrrhetinic acid, increases circulating and therefore, salivary levels of unconjugated deoxycorticosterone and dehydroepiandrosterone by inhibiting their conjugation at source within the adrenal cortex (Al-Dujaili et al, 2011) . This supports the hypothesis that it may be of value in the treatment of PCOS. Glycyrrhiza glabra has also been attributed to a reduction in The third most popular herb utilized by practitioners was Vitex agnus castus.
Interestingly, there have been no large scale studies examining this herb in the treatment of PCOS published in the English language. This questionnaire finding suggests that this is a potentially effective treatment and a prominent herb for future investigation. Vitex agnus castus has been used therapeutically primarily for its dopamegic effects and in the treatment of pre-menstrual syndrome, corpus luteal insufficiency and latent hyperprolactinemia (Mills and Bone 2013) . A small scale survey interviewed 12 practitioners using the herb for different female reproductive conditions (Burgoyne 2011). In this study most practitioners agreed that 3 to 6 months treatment time was necessary to bring about any significant, lasting
improvements. This finding mirrors the start of successful treatment results found in this questionnaire, adding weight to its role in the effective treatment of PCOS.
Although there was no scientific research identified in the literature review, Vitex agnus castus presents a promising subject for future research projects, with successful empirical results in this and other studies.
In terms of the literature review, Cinnamomum verum is well researched in comparison with many other herbs (Table 1) , with particular focus on its hypoglycaemic and hypocholesteremic effects and as a potential treatment for NIDDM (Pham et al, 2007) and metabolic syndrome (Khan et al. 2003) . Wang et al. (2007) have found that Cinnamomum verum extract has an insulin potentiating activity by increasing phosphatidylinositol 3-kinase activity that is present in the aqueous fraction. Cinnamomum verum appears to present promise in terms of treating insulin resistance and hyperinsulinemia which is characteristic of PCOS and additionally, to combat some of the longer term CVD consequences. Importantly, there have been no adverse effects reported in any trials to date and it is a commonly used culinary spice in many cultures.
The potentially important role of ethnobotany in the development of herbal treatment for PCOS is illustrated by research on two herbs. Initial investigation was prompted by traditional use in their respective cultures for symptoms related to PCOS. Research into the herb Mentha spicata was guided by traditional use for M a n u s c r i p t 23 hirsutism in Turkey (Grant, 2012) . A randomised controlled trial by Grant in 2010 indicated that this herb had potential to be a beneficial treatment. In the questionnaire, its use was documented by one practitioner however; a tincture was used rather than an infusion as used in the trial. The research into the herb Labisia pumilla var albta has also been directed by traditional use of the herb in Malaysia for infertility and menstrual disturbances (Manneras et al. 2010) Research to date has only been in rat models but results seem promising as a potential future treatment.
The research on Stachys lavandulifolia indicates effectiveness in treating abnormal uterine bleeding in women with PCOS, however, the higher level of reported adverse events is noted which may affect its suitability for use with patients.
A much longer and larger trial would be welcome to determine this.
Research on the use of Berberine containing herbs presents exciting promise for herbal treatment of women with PCOS. Berberine containing herbs include
Hydrastis candensis, Berberis vulgaris, Berberis aquifolium. The research focuses on patients taking berberine concurrently with an anti-androgen medication, and
shows hypoglycaemic and anti-hyperlipidaemic effects. Importantly, treatment with berberine decreased important risk factors for CVD disease, such as waist hip ratio, waist circumference, triglycerides, total cholesterol and LDL. Furthermore, reported adverse effects with berberine treatment were less than treatment with metformin.
The mechanism of action of berberine on women with PCOS are still unclear. Wu and al. (2006) found that berberine improved insulin resistance in theca cells and granuolsa cells in a similar way to metformin, by modulating androgen production through the activation of AMP-activated protein kinase. Therefore this may be an area for further research to determine this mode of action. A multicentre, randomized, placebo-controlled and double-blind trial has been registered (Yan et al., 2013) A c c e p t e d M a n u s c r i p t
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Weight loss, if appropriate, is also advocated by many herbal practitioners;
confirmed by the scientific research (Kiddy 1992) .
There is increasing evidence that PCOS is not purely a gynaecological disorder but a complex endocrine disorder. The majority of practitioners questioned agreed that insulin resistance is a key factor in PCOS and this is reflected in the bulk of the scientific research (Dunaif 1997 , Teede 2010 . Many of the herbs chosen by the practitioners exert hypoglycaemic effects such as Cinnamomum spp. and Galega officinalis but interestingly, they were not the first three most frequently chosen herbs.
A constant theme that emerged from the review of the literature on PCOS was patient dissatisfaction with pharmacological medical treatment. Metformin, has been heralded as a 'cure' for many of the symptoms of PCOS, but on closer examination, many women suffer debilitating gastro-intestinal side effects and are searching for alternative therapeutic options (Verity, 2012) . In general, herbal treatment seemed to be well tolerated by women with PCOS. Side effects of herbal treatment did not emerge as an issue; although this may have been due to the practitioners not wanting to highlight this kind of information.
Limitations of this research project:
• The survey was distributed to NIMH members only, whilst the largest professional body in the UK it must be recognized that it only represents a fraction of the practitioners of Western herbal medicine.
Consequently, the applicability of the results to the wider herbal community is unclear.
• The numbers of PCOS patients treated by herbal practitioners was not quantified in this preliminary study making impact difficult to assess.
• The response rate of practitioners was low, at 17%, however the other identified published survey with medical herbalists from NIMH using solely email surveys delivered a response rate of 16% (Brock et al, 2012) . Corp and Pendry (2013) utilized postal surveys as well as emails and had a response rate of 26%. Therefore the use of only email surveys in this study may have impacted on the overall response rate.
M a n u s c r i p t
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• The treatment success rate was taken whilst some patients were taking concurrent medications thus confounds the results since this was only taken from the practitioner's viewpoint, which may be biased. • Case study led interviews with herbal practitioners regarding treatment of patients with PCOS.
• Questionnaires of women with PCOS being treated by herbal practitioners, their views on herbal treatment and the use of a validated symptom scale to monitor results. (Validation is important otherwise scales are not scientifically relevant).
• National treatment survey of herbal practitioners to identify numbers of women with PCOS treated by herbal practitioners.
• Study to investigate effectiveness of herbal treatment in women with PCOS wishing fertility outcomes.
• New design of RCT using individualized herbal treatment utilizing herbal placebo formula and treatment (see Flower 2012). Results using validated symptom scales and biochemical tests.
• Further investigation into the safety of herbs whilst taking concurrent medication, in particular, metformin.
Conclusion
This preliminary study concludes that phytotherapy shows a promising role in the treatment of PCOS. Empirical evidence from the questionnaire of herbal practitioners clearly confirms this, with frequent successful results identified.
Evidence from scientific research of herbs in the treatment of PCOS is limited.
However, there are some encouraging results that suggest some herbs may exert hypoglycaemic and anti-androgen actions beneficial in the treatment of PCOS.
Some herbs may additionally, offer cardio-protective benefits reducing long term CVD risk which is becoming increasingly recognised as a significant risk factor for M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t 
